Lombardi Comprehensive Cancer Center publishes manual for childhood cancer survivors

With more than 270,000 childhood cancer survivors living in the United States, researchers have turned their attention to the effects of cancer treatment that can occur years after therapy, called late effects. At the Lombardi Comprehensive Cancer Center and Georgetown University Hospital, a team of oncologists, nurses, social workers and an art therapist have created the first survivorship manual, tailored for each child treated for cancer. The Next Step… Crossing the Bridge to Survivorship is an educational guide designed to provide specific information related to long-term follow-up and survivorship.

“The end of cancer treatment is a time of strong emotions for patients and families,” says Aziza T. Shad, M.D., chief of the division of pediatric hematology oncology at Lombardi and the Hospital, and author of the manual. “Celebration is often mixed with anxiety and loss of security. Most families feel overwhelmed and have many questions about the future.” Shad, an internationally known pediatric oncologist, is the Amey Distinguished Professor of Neuro-oncology and Childhood Cancer at Georgetown University Medical Center.

Many of those questions center on the future health of the child. Chemotherapy, radiation therapy, and surgery may all have late effects involving any organs or body systems. Some complications can be identified early during treatment and follow-up. The majority of late effects, however, become apparent many years after treatment is finished. Some late effects are easily treated, while others may become chronic.

“Late effects are caused by injury to healthy cells as a result of cancer treatment. Just like every person reacts differently to treatment, late effects also vary from person to person and cancer to cancer,” Shad’s manual explains. “A lot depends on the types of therapy and the doses used. Chemotherapy and radiation therapy cause most of the late effects.”

Some examples of late effects from treatment include heart disease after treatment with anthracycline chemotherapy or high-dose chest radiation, learning disabilities in survivors treated with radiation and/or chemotherapy to the brain, breast cancer at an early age in female survivors of Hodgkin's disease who received chest and neck radiation in their teens, second cancers from chemotherapy drugs or radiation used to treat the original cancer, symptoms of post-traumatic stress syndrome in survivors and their parents, and chronic pain and fatigue.

“Thirty years ago, few children with cancer survived, but now almost 80 percent of all children and adolescents diagnosed with cancer are surviving more than 5 years and the majority of them are cured,” explains Shad. “There is much to celebrate in the field of childhood cancer. We hope this manual will help ease the transition for patients and families from active treatment to follow-up care.”

The manual is customized for each patient to include information about their cancer diagnosis and specific treatment. It combines the personal health record with an educational guide about long-term effects. Also, the manual promotes a “shared care” model, incorporating primary care providers as an integral part of a survivor’s care.

“Primary care physicians and nurses can play a pivotal role in the monitoring of potential late effects and survivorship issues,” says Shad.

According to the American Cancer Society, approximately 10,730 children will be diagnosed with cancer this year and 1,490 are expected to die from the disease. At Lombardi, patients who are two years out from treatment are automatically enrolled in the Childhood Cancer Survivorship Program directed by Shad. The program, established in 2003, is also open to all childhood cancer survivors, regardless of where they received treatment. It focuses on the unique health-care needs of survivors by:

-- Monitoring and managing late effects of therapy
-- Addressing psychosocial needs
-- Educating survivors about their disease and the treatment received
-- Promoting wellness through education on healthy living
-- Encouraging participation in survivorship research
-- Empowering survivors to advocate for their own healthcare needs

Source: Georgetown University

Related stories:

Older renal cancer patients appear to benefit from sorafenib treatment
Older and younger patients with renal cancer derive similar benefit from sorafenib therapy and tolerate the drug equally well, according to a study published online October 7 in the Journal of the National Cancer Institute.
Scientists simulate gut reaction to arsenic exposure
A simulated gastrointestinal system is helping scientists test contaminated soil for its potential to harm humans. The method is likely to save time and money for people hoping to repurpose land with an industrial past.
Mayo researchers explore issues related to multiple myeloma treatment
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.
New therapeutic treatment approach improves survival in esophageal cancer patients
A study released at the 73rd Annual Scientific Meeting of the American College of Gastroenterology in Orlando found that a new therapeutic treatment, when delivered endoscopically and used in combination with chemotherapy and radiation therapy, improved survival rates in patients with locally advanced esophageal cancer. Cancer of the esophagus often has a poor survival rate.
Pediatric study finds alternatives for radiation of low-grade brain tumors
A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma. The study was presented Sunday at the 40th annual International Society of Pediatric Oncology Meeting in Berlin, Germany.
Battling cancer, one cell at a time
New research suggests that the identification and examination of key cell signaling events required for initiation and progression of cancer might be best accomplished at the single cell level. The research, published by Cell Press in the October issue of the journal Cancer Cell, provides new insight that may lead to better diagnosis and treatment of some complex cancers.
Smoking and solid fuel use in homes in China projected to cause millions of deaths
If current levels of smoking and biomass and coal fuel use in homes continues, between 2003 and 2033 there will be an estimated 65 million deaths from chronic obstructive pulmonary disease (COPD) and 18 million deaths from lung cancer in China, accounting for 19% and 5% of all deaths in that country during this period.
Nanodiamond drug device could transform cancer treatment
A Northwestern University research team has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed.

News discussion:

Medicine & Health news